Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Therapeutics

Life Sciences

Health Care

Biotechnology

Enterome

Belichard Pierre

Lucie Rouch

Joao G. Magalhaes

Pierre Sahakian

Marie-Laure Bouttier

Joel Richard, PhD, HDR

Jean-Michel Paillarse

Jan Fagerberg

Christelle Dumoussaud

Research and Development

Leadership Team

Clinical Development

��

Teams at Enterome

Research and Development

Leadership Team

Clinical Development

��������

Teams at Enterome

Research and Development

Leadership Team

Clinical Development

��